Journal
Frontiers in Neuroscience
Publication Date
2019
Volume
13
Inclusive Pages
394
Document Type
Open Access Publication
DOI
10.3389/fnins.2019.00394
Rights and Permissions
Kennedy AD, Pappan KL, Donti T, Delgado MR, Shinawi M, Pearson TS, Lalani SR, Craigen WE, Sutton VR, Evans AM, Sun Q, Emrick LT and Elsea SH (2019) 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis. Front. Neurosci. 13:394. doi: 10.3389/fnins.2019.00394 © 2019 Kennedy, Pappan, Donti, Delgado, Shinawi, Pearson, Lalani, Craigen, Sutton, Evans, Sun, Emrick and Elsea. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Kennedy, Adam D.; Pappan, Kirk L.; Donti, Taraka; Delgado, Mauricio R.; Shinawi, Marwan; Pearson, Toni S.; Lalani, Seema R.; Craigen, William E.; Sutton, V. Reid; Evans, Anne M.; Sun, Qin; Emrick, Lisa T.; and Elsea, Sarah H., "2-pyrrolidinone and succinimide as clinical screening biomarkers for GABA-transaminase deficiency: Anti-seizure medications impact accurate diagnosis." Frontiers in Neuroscience. 13, 394. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7791
